About NuMedii
NuMedii is a Healthcare company based in Menlo Park (United States) founded in 2008. Provider of data to discover new medicine. NuMedii has raised $3.5 million across 1 funding round from investors including Lightspeed Venture Partners, Claremont Creek Ventures and Life Science Angels. NuMedii offers products and services including AI Drug Discovery Platform. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its legal entity is NuMedii, Inc. Its competitors include Insitro, BridgeBio and Forge Biologics; 3 of its 3 listed competitors have raised funding.
Company details
NuMedii was founded in 2008 and is based in Menlo Park, United States. Operations focus on the biotechnology sector, where data from various sources is combined with proprietary network-based algorithms. Drug candidates are identified, and biomarkers predictive of efficacy for specific diseases are developed. This approach translates data into therapies, reducing risks associated with new drug development.
- Headquarters Menlo Park, United States
- SectorsHealthcare
- Website numedii.com
- Social LinkedIn X Facebook
- Legal Name Numedii, Inc.
- Total Equity Funding$3.5M (USD)
in 1 rounds
- Latest Funding Round$3.5M (USD), Series A
Jun 2013
- InvestorsLightspeed Venture Partners
& 2 more
Products & Services of NuMedii
NuMedii offers a comprehensive portfolio of products and services, including AI Drug Discovery Platform.
Uses AI and big data to identify drug candidates for precision therapeutics
Funding Insights of NuMedii
NuMedii has successfully raised a total of $3.5M through 1 strategic funding round. The most recent funding activity was a Series A round of $3.5 million completed in June 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.5M
- Total Rounds 1
- Last Round Series A — $3.5M
- First Round $3.5M
(Jun 2013)
- Investors Count 3
All 1 funding rounds of NuMedii with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2013 | $3.5M | Series A | – | – |
3 investors in total: 3 institutional.
Investors in NuMedii
NuMedii has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Lightspeed Venture Partners, Claremont Creek Ventures and Life Science Angels.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Seed and early-stage venture capital firm investing in digital solutions for healthcare and energy industries. | claremontcreek.com | |||
Venture capital investing in innovative companies across global sectors is undertaken by Lightspeed Venture Partners. | 1997 | lsvp.com | Menlo Park, United States | |
Life sciences startups are funded by a non-profit angel network. | lifescienceangels.com | Sunnyvale, United States |
Investor details for NuMedii
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of NuMedii
19 people are tracked at NuMedii (2 in leadership, 17 in board & advisors).
| Name | Role | Group |
|---|---|---|
Gini Deshpande | Founder & CEO | Leadership |
Linda De Young | Head, Product Development | Leadership |
Joel Dudley | Scientific Advisor | Board & advisors |
Mark Murcko | Chair, Scientific Advisory Board | Board & advisors |
Atul Butte | Scientific Advisor | Board & advisors |
Samuel Saks | Chair, Clinical Advisory Board | Board & advisors |
Paul Wolters | Advisor | Board & advisors |
Toby Maher | Advisor | Board & advisors |
Naftali Kaminski | Advisor | Board & advisors |
Kevin Brown | Advisor | Board & advisors |
Zea Borok | Advisor | Board & advisors |
Nicholas Schork | Scientific Advisor | Board & advisors |
Bill Baer | Clinical Advisor | Board & advisors |
Pankaj Pasricha | Clinical Advisor | Board & advisors |
Gisli Jenkins | Advisor | Board & advisors |
Suneel Gupta | Clinical Advisor | Board & advisors |
Zemin Zhang | Scientific Advisor | Board & advisors |
Eric Perakslis | Scientific Advisor | Board & advisors |
Eric Schadt | Scientific Advisor | Board & advisors |
Complete people profiles for NuMedii
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of NuMedii
2 dated milestones of NuMedii across 5 years, from founding to its latest funding, stage changes and deals.
- Founded NuMedii is founded.
- Funding First funding round of $3.5M.
Competitors of NuMedii
NuMedii has 3 listed competitors in our database, 3 of them funded. They include Insitro, BridgeBio and Forge Biologics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. |
Detailed competitors of NuMedii
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of NuMedii
Websites that share an audience with NuMedii (numedii.com).
Websites whose visitors overlap most with NuMedii. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| personalis.com | 87% | 15K | #748,077 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as NuMedii (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Numedii
Complete news archive for NuMedii
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NuMedii
NuMedii was founded in 2008 and raised its 1st funding round 5 years after it was founded.
NuMedii is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
NuMedii is a funded company, having raised a total of $3.5M across 1 funding round to date. The company's 1st funding round was a Series A of $3.5M, raised on Jun 2013.
NuMedii was founded in 2008 and is based in Menlo Park, United States. Operations focus on the biotechnology sector, where data from various sources is combined with proprietary network-based algorithms. Drug candidates are identified, and biomarkers predictive of efficacy for specific diseases are developed. This approach translates data into therapies, reducing risks associated with new drug development.
NuMedii's top competitors include BridgeBio, Forge Biologics and Insitro.
NuMedii offers AI Drug Discovery Platform.
NuMedii has 3 investors. Key investors include Lightspeed Venture Partners, Claremont Creek Ventures, and Life Science Angels.
NuMedii operates through Numedii, Inc..